Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Journal of Cancer Survivorship
Erschienen in: Journal of Cancer Survivorship 4/2018

04.05.2018 | Review

Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment

verfasst von: Victoria J. Bray, Haryana M. Dhillon, Janette L. Vardy

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cognitive symptoms are common in cancer patients, with up to 70% reporting cognitive symptoms following chemotherapy. These symptoms can have a major impact on how an individual functions in all aspects of their lives. This review evaluates self-reported cognitive function and its associations with neuropsychological tests and patient-reported outcomes in adult cancer patients who received chemotherapy treatment for a solid cancer.

Methods

A search of multiple databases (Medline, Ovid at Nursing, PsycINFO, Allied and Complementary Medicine) from 1936 to 2017 was conducted, identifying 1563 unique articles, of which 101 met inclusion criteria.

Results

Of the 101 included studies, 48 (47%) were cross-sectional and 38 (38%) longitudinal in design, with 12 (12%) randomised controlled trials. A minority (26%) incorporated a healthy control arm in the study design, whilst the majority (79%) were in women with breast cancer. There was diversity in the assessment of self-reported cognitive symptoms. A total of 43 of 44 studies that sought an association between self-reported cognitive function and patient-reported outcomes found a moderate to strong association. Overall, 31 studies showed a lack of association between self-reported cognitive symptoms and neuropsychological results, whilst 14 studies reported a significant association between the two, but the association was often restricted to limited cognitive domains.

Conclusion

The review found widespread heterogeneity in the assessment of self-reported cognitive symptoms and consistently absent or weak association with neuropsychological test scores.

Implications for Cancer Survivors

This research highlights the need for a standardised approach to measurement of self-reported cognitive symptoms in cancer patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3:232–3.CrossRef
2.
Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222–33.PubMedCrossRef
3.
Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87.PubMedPubMedCentralCrossRef
4.
Koppelmans V, Breteler MM, Boogerd W, et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol. 2012;30:1080–6.PubMedCrossRef
5.
Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13:1387–97.PubMedCrossRef
6.
Richardson-Vejlgaard R, Dawes S, Heaton RK, Bell MD. Validity of cognitive complaints in substance-abusing patients and non-clinical controls: the Patient’s Assessment of Own Functioning Inventory (PAOFI). Psychiatry Res. 2009;169:70–4.PubMedPubMedCentralCrossRef
7.
Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol. 1997;50:441–50.PubMedCrossRef
8.
Wagner L, Sweet J, Butt Z, et al. Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy - Cognitive Function instrument. The Journal of Supportive Oncology. 2009;7:W32–9.
9.
Joly F, Giffard B, Rigal O, de Ruiter MB, Small BJ, Dubois M, et al. Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force symposium and update since 2012. J Pain Symptom Manag. 2015;50:830–41.CrossRef
10.
Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet Oncology. 2011;12:703–8.PubMedCrossRef
11.
Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19:623–9.PubMedCrossRef
12.
van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210–8.PubMedCrossRef
13.
Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640–50.PubMedCrossRef
14.
Hermelink K. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2011;117:1103–4.PubMedCrossRef
15.
Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828–34.PubMedPubMedCentralCrossRef
16.
Vardy J, Wong K, Yi QL, Park A, Maruff P, Wagner L, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14:1111–8.PubMedCrossRef
17.
Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33:4085–92.PubMedPubMedCentralCrossRef
18.
Von AD, Habermann B, Carpenter JS, Schneider BL. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs. 2013;17:236–41.CrossRef
19.
Myers JS. Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum. 2012;39:E31–40.PubMedCrossRef
20.
Kmet LML, Robert C.; Cook, Linda S. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta Heritage Foundation for Medical Research 2004.
21.
Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–93.PubMedCrossRef
22.
Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110:143–52.PubMedCrossRef
23.
Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434–40.PubMedPubMedCentralCrossRef
24.
Amidi A, Christensen S, Mehlsen M, Jensen AB, Pedersen AD, Zachariae R. Long-term subjective cognitive functioning following adjuvant systemic treatment: 7-9 years follow-up of a nationwide cohort of women treated for primary breast cancer. Br J Cancer. 2015;113:794–801.PubMedPubMedCentralCrossRef
25.
Anstey KJ, Sargent-Cox K, Cherbuin N, Sachdev PS. Self-reported history of chemotherapy and cognitive decline in adults aged 60 and older: the PATH through life project. Journals of Gerontology Series A-Biological Sciences & Medical Sciences. 2015;70:729–35.CrossRef
26.
Apple AC, Ryals AJ, Alpert KI, Wagner LI, Shih PA, Dokucu M, et al. Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. NeuroImage: Clinical. 2017;14:685–91.CrossRef
27.
Askren MK, Jung M, Berman MG, Zhang M, Therrien B, Peltier S, et al. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Breast Cancer Research & Treatment. 2014;147:445–55.CrossRef
28.
Barton DL, Burger K, Novotny PJ, Fitch TR, Kohli S, Soori G, et al. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer. 2013;21:1185–92.PubMedCrossRef
29.
Bastani P, Ahmad Kiadaliri A. Health-related quality of life after chemotherapy cycle in breast cancer in Iran. Med Oncol. 2011;28(Suppl 1):S70–4.PubMedCrossRef
30.
Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology. 2006;15:422–30.PubMedCrossRef
31.
Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. European Journal of Cancer Care (English Language Edition). 2012;21:485–92.CrossRef
32.
Bond SM, Dietrich MS, Murphy BA. Neurocognitive function in head and neck cancer patients prior to treatment. Support Care Cancer. 2012;20:149–57.PubMedCrossRef
33.
Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D, et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol. 2017;35:217–25.PubMedCrossRef
34.
Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psycho-Oncology. 2012;21:43–53.PubMedCrossRef
35.
Buchanan ND, Dasari S, Rodriguez JL, Lee Smith J, Hodgson ME, Weinberg CR, et al. Post-treatment neurocognition and psychosocial care among breast cancer survivors. Am J Prev Med. 2015;49:S498–508.PubMedPubMedCentralCrossRef
36.
Carlsson M, Strang P, Bjurstrom C. Treatment modality affects long-term quality of life in gynaecological cancer. Anticancer Res. 2000;20:563–8.PubMed
37.
Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.PubMedCrossRef
38.
Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, et al. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014;67:811–20.PubMedCrossRef
39.
Cheung YT, Lim SR, Shwe M, Tan YP, Chan A. Psychometric properties and measurement equivalence of the English and Chinese versions of the functional assessment of cancer therapy-cognitive in Asian patients with breast cancer. Value Health. 2013;16:1001–13.PubMedCrossRef
40.
Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol. 2015;26:1446–51.PubMedPubMedCentralCrossRef
41.
Cheung YT, Shwe M, Chui WK, Chay WY, Ang SF, Dent RA, et al. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbance in Asian breast cancer patients. Ann Pharmacother. 2012;46:1645–55.PubMedCrossRef
42.
Collins B, Paquet L, Dominelli R, White A, MacKenzie J. Metamemory function in chemotherapy-treated patients with breast cancer: an explanation for the dissociation between subjective and objective memory measures? Psycho-Oncology. 2017;26:109–17.PubMedCrossRef
43.
Conroy SK, McDonald BC, Smith DJ, et al. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Research & Treatment. 2013;137:493–502.CrossRef
44.
Cruzado JA, Lopez-Santiago S, Martinez-Marin V, et al. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer. 2014;22:1815–23.PubMedCrossRef
45.
de Ruiter MB, Liesbeth R, Boogard W, et al. Cerebral hyporesponsiveness and cognitive impairment: 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206–19.PubMedCrossRef
46.
Debess J, Riis JO, Engebjerg MC, Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat. 2010;121:91–100.PubMedCrossRef
47.
Deprez S, Amant F, Smeets A, Peeters R, Leemans A, van Hecke W, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81.PubMedCrossRef
48.
Deprez S, Vandenbulcke M, Peeters R, Emsell L, Smeets A, Christiaens MR, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activation during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32:2031–8.PubMedCrossRef
49.
Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499–507.PubMedPubMedCentralCrossRef
50.
Downie FP, Mar Fan HG, Houede-Tchen N, et al. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006;15:921–30.PubMedCrossRef
51.
Dumas JA, Makarewicz J, Schaubhut GJ, Devins R, Albert K, Dittus K, et al. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging Behav. 2013;7:524–32.PubMedCrossRef
52.
Fairbanks JMA. Longitudinal study of the effects of chemotherapy on cognitive functioning in breast cancer. Dissertation Abstracts International: Section B: The Sciences and Engineering. 2009;69:5799.
53.
Ferguson RJ, Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007;16:772–7.PubMedPubMedCentralCrossRef
54.
Ferguson RJ, McDonald BC, Rocque MA, et al. Development of CBT for chemotherapy-related cognitive change: results of waitlist control trial. Psychooncology. 2012;21:176–86.PubMedCrossRef
55.
Ferguson RJP, Sigmon STP, Pritchard AJMPH, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer. 2016;122:1782–91.PubMedCrossRef
56.
Fitzpatrick TR, Edgar L, Holcroft C. Assessing the relationship between physical fitness activities, cognitive health, and quality of life among older cancer survivors. J Psychosoc Oncol. 2012;30:556–72.PubMedCrossRef
57.
Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DHS, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. Journal of the National Cancer Instiute. 2013;105:791–801.CrossRef
58.
Ganz PA, Petersen L, Castellon SA, Bower JE, Silverman DHS, Cole SW, et al. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol. 2014;32:3559–67.PubMedPubMedCentralCrossRef
59.
Hermelink K, Küchenhoff H, Untch M, Bauerfeind I, Lux MP, Bühner M, et al. Two different sides of ‘chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psycho-Oncology. 2010;19:1321–8.PubMedCrossRef
60.
Hermelink K, Bühner M, Sckopke P et al. Chemotherapy and post-traumatic stress in the causation of cognitive dysfunction in breast cancer patients. JNCI: Journal of the National Cancer Institute 2017; 109: djx057-djx057.
61.
Hess LM, Huang HQ, Hanlon AL, Robinson WR, Johnson R, Chambers SK, et al. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;139:541–5.PubMedPubMedCentralCrossRef
62.
Iconomou G, Mega V, Koutras A, Iconomou AV, Kalofonos HP. Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer. 2004;101:404–11.PubMedCrossRef
63.
Iconomou G, Koutras A, Karaivazoglou K, Kalliolias GD, Assimakopoulos K, Argyriou AA, et al. Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. European Journal of Cancer Care. 2008;17:535–41.PubMedCrossRef
64.
Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017;35:506–14.PubMedCrossRef
65.
Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19:1647–56.PubMedCrossRef
66.
Janz NK, Mujahid M, Chung LK, Lantz PM, Hawley ST, Morrow M, et al. Symptom experience and quality of life of women following breast cancer treatment. J Women’s Health. 2007;16:1348–61.CrossRef
67.
Jaremka LM, Peng J, Bornstein R, Alfano CM, Andridge RR, Povoski SP, et al. Cognitive problems among breast cancer survivors: loneliness enhances risk. Psycho-Oncology. 2014;23:1356–64.PubMedPubMedCentralCrossRef
68.
69.
Joly F, Lange M, Rigal O, Correia H, Giffard B, Beaumont JL, et al. French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3. Support Care Cancer. 2012;20:3297–305.PubMedCrossRef
70.
Jung MS, Zhang M, Askren MK, Berman MG, Peltier S, Hayes DF, et al. Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis. Brain Imaging Behav. 2017;11:86–97.PubMedCrossRef
71.
72.
Kesler S, Hadi Hosseini S, Heckler C, et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer. 2013;13:299–306.PubMedPubMedCentralCrossRef
73.
Komatsu H, Yagasaki K, Yamauchi H, Yamauchi T, Takebayashi T. A self-directed home yoga programme for women with breast cancer during chemotherapy: a feasibility study. Int J Nurs Pract. 2016;22:258–66.PubMedCrossRef
74.
Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2005;94:53–61.PubMedCrossRef
75.
Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer. 2006;7:67–78.PubMedCrossRef
76.
Lange M, Giffard B, Noal S, Rigal O, Kurtz JE, Heutte N, et al. Baseline cognitive functions among elderly patients with localised breast cancer. Eur J Cancer. 2014;50:2181–9.PubMedCrossRef
77.
Li J, Yu L, Long Z, Li Y, Cao F. Perceived cognitive impairment in Chinese patients with breast cancer and its relationship with post-traumatic stress disorder symptoms and fatigue. Psycho-Oncology. 2015;24:676–82.PubMedCrossRef
78.
McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30:S117–25.PubMedCrossRef
79.
McDougall GJ, Becker H, Acee TW, et al. Symptom management of affective and cognitive disturbance with a group of cancer survivors. Arch Psychiatr Nurs. 2011;25:24–35.PubMedCrossRef
80.
Mandelblatt JS, Clapp JD. Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). 2016.
81.
Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns. 2007;66:108–18.PubMedCrossRef
82.
Menning S, de Ruiter MB, Veltman DJ, Koppelmans V, Kirschbaum C, Boogerd W, et al. Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment—the role of fatigue. NeuroImage:Clinical. 2015;7:547–54.PubMedPubMedCentralCrossRef
83.
Menning S, de Ruiter MB, Kieffer JM, et al. Cognitive impairment in a subset of breast cancer patients after systemic therapy—results from a longitudinal study. Journal of Pain and Symptom Management. 2016;52:560–9. e561PubMedCrossRef
84.
Merriman JD, Sereika SM, Brufsky AM, McAuliffe PF, McGuire KP, Myers JS, et al. Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. Psycho-Oncology. 2017;26:44–52.PubMedCrossRef
85.
Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers CA, et al. Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology. 2013;22:2354–63.PubMedCrossRefPubMedCentral
86.
Myers JS, Sousa VD, Donovan HS. Predictors of self-reported memory problems in patients with ovarian cancer who have received chemotherapy. Oncol Nurs Forum. 2010;37:596–603.PubMedCrossRef
87.
Myers JS, Wick JA, Klemp J. Potential factors associated with perceived cognitive impairment in breast cancer survivors. Support Care Cancer. 2015;23:3219–28.PubMedPubMedCentralCrossRef
88.
Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Research & Treatment. 2000;64:165–76.CrossRef
89.
Park JH, Bae SH, Jung YS, Jung YM. The psychometric properties of the Korean version of the functional assessment of cancer therapy-cognitive (FACT-Cog) in Korean patients with breast cancer. Support Care Cancer. 2015;23:2695–703.PubMedCrossRef
90.
J-h P, Jung YS, Kim KS, Bae SH. Effects of compensatory cognitive training intervention for breast cancer patients undergoing chemotherapy: a pilot study. Support Care Cancer. 2017;25:1887–96.CrossRef
91.
Pomykala K, Ganz P, Bower J, et al. The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging and Behavior. 2013;7:511–23.PubMedPubMedCentralCrossRef
92.
Poppelreuter M, Weis J, Kulz AK, et al. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer. 2004;40:43–9.PubMedCrossRef
93.
Poppelreuter M, Weis J, Bartsch HH. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol. 2009;27:274–96.PubMedCrossRef
94.
Porter KE. “Chemo brain”—is cancer survivorship related to later-life cognition? Findings from the health and retirement study. Journal of Aging and Health. 2013;25:960–81.PubMedCrossRef
95.
Prokasheva S, Faran Y, Cwikel J, Geffen GB. Analysis of memory deficits following chemotherapy in breast cancer suvivors: evidence from the doors and people test. J Psychosoc Oncol. 2011;29:499–514.PubMedCrossRef
96.
Pullens MJ, De Vries J, Van Warmerdam LJ, et al. Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology. 2013;22:1783–9.PubMedCrossRef
97.
Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009;116:113–23.PubMedCrossRef
98.
Rey D, Bouhnik AD, Mancini J, Bendiane MK, Séror V, Viens P. Self-reported cognitive impairment after breast cancer treatment in young women from the ELIPPSE40 cohort: the long-term impact of chemotherapy. Breast J. 2012;18:406–14.PubMedCrossRef
99.
Schagen SB, Boogerd W, Muller MJ, ten Bokkel Huinink W, Moonen L, Meinhardt W, et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 2008;47:63–70.PubMedCrossRef
100.
Schagen SB, Das E, van Dam FS. The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psychooncology. 2009;18:674–8.PubMedCrossRef
101.
Schagen SB, Das E, Vermeulen I. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psychooncology. 2012;21:1132–5.PubMedCrossRef
102.
Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol. 2009;48:76–85.PubMedCrossRef
103.
Seliktar N, Polek C, Brooks A, Hardie T. Cognition in breast cancer survivors: hormones versus depression. Psycho-Oncology. 2015;24:402–7.PubMedCrossRef
104.
Shaffer VA, Merkle EC, Fagerlin A, Griggs JJ, Langa KM, Iwashyna TJ. Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: findings from a prospective cohort study. Med Care. 2012;50:849–55.PubMedPubMedCentralCrossRef
105.
Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11:6–15.PubMedCrossRef
106.
Skaali T, Fossa SD, Andersson S, et al. Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress. J Psychosom Res. 2011;70:403–10.PubMedCrossRef
107.
Skaali T, Fossa SD, Dahl AA. A prospective study of cognitive complaints in patients with testicular cancer. Clinical Genitourinary Cancer. 2011;9:6–13.PubMedCrossRef
108.
Skoogh J, Steineck G, Stierner U, Cavallin-Ståhl E, Wilderäng U, Wallin A, et al. Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish population-based study 3-26 years after treatment. Acta Oncol. 2012;51:185–97.PubMedCrossRef
109.
Tager FA, McKinley PS, Schnabel FR, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat. 2010;123:25–34.PubMedCrossRef
110.
Von AD, Harvison KW, Monahan PO, et al. Cognitive function in breast cancer survivors compared to healthy age- and education-matched women. Clin Neuropsychol. 2009;23:661–74.CrossRef
111.
Von AD, Carpenter JS, Saykin A, et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2012;135:799–809.CrossRef
112.
Von AD, Tallman EF. Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy-cognitive function instrument. J Pain Symptom Manag. 2015;49:697–706.CrossRef
113.
Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: ‘subjective’ complaints and ‘objective’ neuropsychological test results. Psycho-Oncology. 2009;18:775–82.PubMedCrossRef
114.
Zamurovic M, Mitrovic-Jovanovic A, Jurisic A. Ovarian carcinoma patients—life quality analysis in the postoperative period—how to improve it? Eur J Gynaecol Oncol. 2010;31:672–4.PubMed
115.
Tannock I, Ahles T, Ganz P, van Dam F. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22:2233–9.PubMedCrossRef
116.
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–9.PubMedCrossRef
117.
Vardy JL, Dhillon H, Xu W et al. Cognitive function and fatigue in colorectal cancer (CRC) patients: baseline assessments prior to chemotherapy. In ASCO Meeting Abstracts. Chicago, USA: 2009; 9557.
118.
Wefel JS, Lenzi R, Theriault RL, Buzdar AU, Cruickshank S, Meyers CA. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer. 2004;101:466–75.PubMedCrossRef
119.
Player L, Mackenzie L, Willis K, Loh SY. Women’s experiences of cognitive changes or ‘chemobrain’ following treatment for breast cancer: a role for occupational therapy? Aust Occup Ther J. 2014;61:230–40.PubMedCrossRef
120.
Galantino ML, Greene L, Daniels L, Dooley B, Muscatello L, O’Donnell L. Longitudinal impact of yoga on chemotherapy-related cognitive impairment and quality of life in women with early stage breast cancer: a case series. Explore: The Journal of Science & Healing. 2012;8:127–35.CrossRef
121.
Smidt K, Mackenzie L, Dhillon H, Vardy J, Lewis J, Loh SY. The perceptions of Australian oncologists about cognitive changes in cancer survivors. Support Care Cancer. 2016;24:4679–87.PubMedCrossRef
Metadaten
Titel
Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment
verfasst von
Victoria J. Bray
Haryana M. Dhillon
Janette L. Vardy
Publikationsdatum
04.05.2018
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 4/2018
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-018-0692-x

Weitere Artikel der Ausgabe 4/2018

Journal of Cancer Survivorship 4/2018 Zur Ausgabe

OriginalPaper

An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation

OriginalPaper

Associations between physical activity and comorbidities in Korean cancer survivors

OriginalPaper

Are the effects of cognitive behavior therapy for severe fatigue in cancer survivors sustained up to 14 years after therapy?

OriginalPaper

Childbirth after adolescent and young adult cancer: a population-based study

OriginalPaper

Validity of self-reported weight, height, and body mass index among African American breast cancer survivors

Review

Physical decline and its implications in the management of oesophageal and gastric cancer: a systematic review

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise